Catheter Precision, Inc. (NYSEAMERICAN:VTAK) Short Interest Update

Catheter Precision, Inc. (NYSEAMERICAN:VTAK) saw a large decrease in short interest in the month of February. As of February 27th, there was short interest totaling 75,311 shares, a decrease of 32.7% from the February 12th total of 111,873 shares. Based on an average daily volume of 54,415 shares, the short-interest ratio is presently 1.4 days. Currently, 4.6% of the company’s shares are sold short. Currently, 4.6% of the company’s shares are sold short. Based on an average daily volume of 54,415 shares, the short-interest ratio is presently 1.4 days.

Catheter Precision Price Performance

Shares of NYSEAMERICAN:VTAK traded down $0.11 during trading on Friday, hitting $1.37. 141,223 shares of the company’s stock were exchanged, compared to its average volume of 1,348,230. The company has a quick ratio of 0.46, a current ratio of 0.46 and a debt-to-equity ratio of 0.20. The firm has a 50-day moving average price of $1.82 and a two-hundred day moving average price of $2.17. Catheter Precision has a 1-year low of $1.14 and a 1-year high of $15.68.

Institutional Trading of Catheter Precision

A hedge fund recently bought a new stake in Catheter Precision stock. Millennium Management LLC purchased a new position in Catheter Precision, Inc. (NYSEAMERICAN:VTAK) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm purchased 34,721 shares of the company’s stock, valued at approximately $64,000. Millennium Management LLC owned about 2.08% of Catheter Precision as of its most recent SEC filing. Hedge funds and other institutional investors own 20.34% of the company’s stock.

About Catheter Precision

Catheter Precision, Inc (NYSE American: VTAK) is a medical device company specializing in the design, development and manufacture of catheter-based products for interventional cardiology and peripheral vascular procedures. The company’s core business centers on balloon catheter platforms, offering both standard and specialty catheter configurations that address applications ranging from percutaneous transluminal angioplasty (PTA) to percutaneous transluminal coronary angioplasty (PTCA). Catheter Precision’s product portfolio is engineered to meet diverse clinical needs, including high-pressure dilation, scored and cutting balloon therapies, and drug-coated balloon delivery.

All of Catheter Precision’s products are developed in its ISO 13485-certified, FDA-registered manufacturing facility in Bloomington, Minnesota.